{"nctId":"NCT01302691","briefTitle":"MK-0954E Study in Participants With Hypertension (MK-0954E-357)","startDateStruct":{"date":"2011-01-01","type":"ACTUAL"},"conditions":["Hypertension"],"count":327,"armGroups":[{"label":"L50/H12.5/A5","type":"EXPERIMENTAL","interventionNames":["Drug: losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)","Drug: Placebo to losartan potassium","Drug: Placebo to amlodipine besylate"]},{"label":"L50 + A5","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Losartan potassium","Drug: Amlodipine besylate","Drug: Placebo to MK-0954E"]}],"interventions":[{"name":"losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)","otherNames":[]},{"name":"Losartan potassium","otherNames":[]},{"name":"Amlodipine besylate","otherNames":[]},{"name":"Placebo to MK-0954E","otherNames":[]},{"name":"Placebo to losartan potassium","otherNames":[]},{"name":"Placebo to amlodipine besylate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria\n\n* Participant has a diagnosis of essential hypertension.\n* Participant is being treated with single or dual treatment for hypertension and will be able to discontinue the prior antihypertensive medication.\n* Participant has a mean trough SiDBP of ≥ 90 mmHg and \\< 110 mmHg.\n* Participant has a mean trough SiSBP of ≥ 140 mmHg and \\< 200 mmHg.\n* Participant has no clinically significant abnormality at screening visit.\n\nExclusion criteria\n\n* Participant is currently taking \\> 2 antihypertensive medications.\n* Participant has a history of significant multiple and/or severe allergies to ingredients of Nu-Lotan or Preminent, amlodipine or dihydropyridine drug, and thiazide drug or related drug (i.e., sulfonamide-containing \"chlortalidone\" medicines).\n* Participant is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history within the last year of drug or alcohol abuse or dependence.\n* Participant is pregnant or breastfeeding, or expecting to conceive OR the pregnancy test is positive at screening visit (Visit 1).\n* Participant is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Mean Trough Sitting Diastolic Blood Pressure (SiDBP)","description":"Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.1","spread":null},{"groupId":"OG001","value":"-8.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Experience ≥1 Adverse Event (AE)","description":"An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who experienced at least 1 AE during the 10-week treatment and follow-up period were summarized by study drug received.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.5","spread":null},{"groupId":"OG001","value":"28.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Experience ≥1 Drug-related AE","description":"An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Percentage of participants that experienced at least 1 AE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":null},{"groupId":"OG001","value":"3.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Experience ≥1 Serious Adverse Event (SAE)","description":"An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. The percentage of participants who experienced at least 1 SAE during the 10-week treatment and follow-up period were summarized by study drug received.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Experience ≥1 Drug-related SAE","description":"An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. Percentage of participants that experienced at least 1 SAE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Had Study Drug Stopped Due to an AE","description":"An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who had study drug stopped during the 8-week treatment period due to an AE regardless of whether or not they completed the study was summarized by treatment arm","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Mean Trough Sitting Systolic Blood Pressure (SiSBP)","description":"Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.4","spread":null},{"groupId":"OG001","value":"-10.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":164},"commonTop":["Nasopharyngitis"]}}}